Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England

Persson, M.S.M.; Harman, K.E.; Thomas, Kim; Chalmers, Joanne; Vinogradova, Yana; Langan, S.M.; Hippisley-Cox, J.; Gran, Sonia

Abstract

Background
Trials of novel agents are required to improve the care of patients with rare diseases, but trial feasibility may be uncertain due to concerns over insufficient patient numbers. We aimed to determine the size of the pool of potential participants in England 2015–2017 for trials in the autoimmune blistering skin disease bullous pemphigoid.

Methods
The size of the pool of potential participants was estimated using routinely collected healthcare data from linked primary care (Clinical Practice Research Datalink; CPRD) and secondary care (Hospital Episode Statistics; HES) databases. Thirteen consultant dermatologists were surveyed to determine the likelihood that a patient would be eligible for a trial based on the presence of cautions or contra-indications to prednisolone use. These criteria were applied to determine how they influenced the potential pool of participants.

Results
Extrapolated to the population of England, we would expect approximately 10,800 (point estimate 10,747; 95% CI 7191 to 17,239) new cases of bullous pemphigoid to be identified in a three-year period. For a future trial involving oral prednisolone (standard care), the application of cautions to its use as exclusion criteria would result in approximately 365 potential participants unlikely to be recruited, a further 5332 could be recruited with caution, and 5104 in whom recruitment is still possible. 11–17% of potential participants may have pre-existing dementia and require an alternative consent process.

Conclusions
Routinely collected electronic health records can be used to inform the feasibility of clinical trials in rare diseases, such as whether recruitment is feasible nationally and how long recruitment might take to meet recruitment targets. Future trials of bullous pemphigoid in England may use the data presented to inform trial design, including eligibility criteria and consent processes for enrolling people with dementia.

Citation

Persson, M., Harman, K., Thomas, K., Chalmers, J., Vinogradova, Y., Langan, S., …Gran, S. (2021). Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England. BMC Medical Research Methodology, 21(1), Article 22. https://doi.org/10.1186/s12874-021-01212-1

• Journal Article Type: Article
• Acceptance Date: Jan 19, 2021
• Online Publication Date: Feb 4, 2021
• Publication Date: Feb 4, 2021
• Deposit Date: Mar 3, 2021
• Publicly Available Date: Mar 4, 2021
• Journal: BMC Medical Research Methodology
• Electronic ISSN: 1471-2288
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 21
• Issue: 1
• Article Number: 22
• DOI: https://doi.org/10.1186/s12874-021-01212-1
• Keywords: Health Informatics; Epidemiology
• Public URL: https://nottingham-repository.worktribe.com/output/5317107
• Publisher URL: https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01212-1